Your session is about to expire
← Back to Search
Immunosuppressant
Tacrolimus for Hereditary Hemorrhagic Telangiectasia
Phase 2
Waitlist Available
Led By Marie E Faughnan, MD,MSc,FRCPC
Research Sponsored by Unity Health Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age > 18 years
Clinical HHT diagnosis or personal genetic diagnosis of HHT
Must not have
Specific contra-indications for study drug (detailed in the product monograph)
Acute infection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, weeks; 12,18,24,30,36,42,48,60,66,72,78,84,96
Awards & highlights
No Placebo-Only Group
Summary
This trial tests oral low-dose tacrolimus for patients with a condition that causes severe nosebleeds. Tacrolimus helps by reducing new blood vessel growth and inflammation, which can decrease bleeding.
Who is the study for?
This trial is for adults over 18 with Hereditary Hemorrhagic Telangiectasia (HHT) who suffer from frequent nosebleeds, at least 15 minutes per week. Participants must have a clinical or genetic diagnosis of HHT and at least one visible telangiectasia. Pregnant or breastfeeding women, those not using effective contraception, people with certain allergies, acute infections, high creatinine levels, liver issues, abnormal ECGs or unstable illnesses cannot join.
What is being tested?
The study tests if low-dose tacrolimus capsules taken orally can reduce the severity of nosebleeds in HHT patients. It will also look for changes in vascular malformations and biomarkers related to HHT in blood and tissue. This Phase II trial involves giving subjects the drug twice daily for six months.
What are the potential side effects?
Tacrolimus may cause side effects such as increased risk of infection due to immune system suppression, kidney problems reflected by elevated creatinine levels, potential liver dysfunction indicated by raised transaminase levels (AST/ALT), and possible heart rhythm abnormalities detectable on an ECG.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am older than 18 years.
Select...
I have been diagnosed with HHT either through clinical evaluation or genetic testing.
Select...
I have nosebleeds lasting 15 minutes or more each week.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have no known allergies or reactions to the study drug.
Select...
I currently have an infection.
Select...
I am not pregnant, breastfeeding, nor planning to become pregnant during the study.
Select...
I am a man and my partner can have children but we are not using effective birth control.
Select...
My liver enzymes are twice as high as the normal limit.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, weeks; 12,18,24,30,36,42,48,60,66,72,78,84,96
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, weeks; 12,18,24,30,36,42,48,60,66,72,78,84,96
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
The change in epistaxis (nose bleeding) severity using low-dose Tacrolimus
Secondary study objectives
Change in Biomarkers
Change in Chronic Bleeding
Change in Epistaxis Severity Score (ESS)
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tacrolimus immediate-release capsulesExperimental Treatment1 Intervention
subjects will be treated with a 6 months course of oral low-dose tacrolimus capsules to be taken twice daily starting dose of 0.025 mg/kg/day, adjusted to maintain drug blood levels of 2-5ng/ml
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Tacrolimus, a calcineurin inhibitor, works by suppressing the immune system and reducing inflammation. It inhibits the activity of T-cells, which are crucial in the immune response, thereby decreasing the production of inflammatory cytokines.
This mechanism is particularly relevant for Osler-Weber-Rendu Syndrome (HHT) patients because it can help reduce the severity of recurrent nasal hemorrhages, a common and debilitating symptom of the disease. By targeting the underlying inflammatory pathways, Tacrolimus may help in managing the vascular malformations characteristic of HHT, potentially improving the quality of life for these patients.
Effect of olfactory ensheathing cells combined with chitosan on inhibition of P2×4 receptor over-expression-mediated neuropathic pain.Characteristics of Taiwanese patients of PNH in the international PNH registry.Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Effect of olfactory ensheathing cells combined with chitosan on inhibition of P2×4 receptor over-expression-mediated neuropathic pain.Characteristics of Taiwanese patients of PNH in the international PNH registry.Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Find a Location
Who is running the clinical trial?
Unity Health TorontoLead Sponsor
556 Previous Clinical Trials
454,376 Total Patients Enrolled
United States Department of DefenseFED
901 Previous Clinical Trials
332,935 Total Patients Enrolled
Marie E Faughnan, MD,MSc,FRCPCPrincipal InvestigatorUnity Health Toronto
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am older than 18 years.I have been diagnosed with HHT either through clinical evaluation or genetic testing.I have no known allergies or reactions to the study drug.I currently have an infection.Your heart's electrical activity is not normal and the QTc measurement is greater than 480msec.I am not pregnant, breastfeeding, nor planning to become pregnant during the study.I am a man and my partner can have children but we are not using effective birth control.Your creatinine levels are higher than the normal range.You are allergic to the study drug or similar medications.My liver enzymes are twice as high as the normal limit.Your BHCG level is below 6 IUL (if it's 6-24 IUL, it will be tested again).I have nosebleeds lasting 15 minutes or more each week.You have at least one visible blood vessel (on the skin or inside the body) that can be examined with a special camera.
Research Study Groups:
This trial has the following groups:- Group 1: Tacrolimus immediate-release capsules
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger